aTyr Pharma, Inc. (ATYR)
| Market Cap | 14.96M -81.5% |
| Revenue (ttm) | 190,000 -19.1% |
| Net Income | -60.81M |
| EPS | -24.86 |
| Shares Out | 2.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,539 |
| Open | 5.70 |
| Previous Close | 6.03 |
| Day's Range | 5.70 - 6.64 |
| 52-Week Range | 4.07 - 44.40 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 114.29 (+1,773.61%) |
| Earnings Date | Nov 5, 2026 |
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn... [Read more]
Financial Performance
In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ATYR stock is "Buy." The 12-month stock price target is $114.29, which is an increase of 1,773.61% from the latest price.
News
aTyr Pharma price target lowered to split-adjusted $6 at RBC Capital
RBC Capital lowered the firm’s price target on aTyr Pharma (ATYR) to $6 from $40 and keeps a Sector Perform rating on the shares. The firm is adjusting its model…
aTyr Pharma price target lowered to $35 from $280 at Piper Sandler
Piper Sandler lowered the firm’s price target on aTyr Pharma (ATYR) to $35 from $280 post reverse stock split, while keeping an Overweight rating on the shares. The firm notes…
aTyr Pharma reports Q3 EPS ($7.43), consensus ($4.00)
“During the last quarter we reached alignment with the U.S. Food and Drug Administration on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary…
aTyr Pharma Earnings release: Q3 2026
aTyr Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
aTyr Pharma Quarterly report: Q3 2026
aTyr Pharma has published its Q3 2026 quarterly earnings report on November 5, 2026.
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...
aTyr Pharma Inc trading halted, news pending
19:50 EDT aTyr Pharma (ATYR) Inc trading halted, news pending
aTyr Pharma announces 1-for-40 reverse stock split
aTyr Pharma (ATYR) announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-40, effective at 5:00 p.m. ET on…
aTyr Pharma Announces One-for-40 Reverse Stock Split
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma, Albert Einstein College of Medicine enter ATYR2810 pact
aTyr Pharma (ATYR) announced a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810, the company’s monoclonal antibody that targets the ne...
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma publishes ATYR0101 data in Journal of Biological Chemistry
aTyr Pharma (ATYR) announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. ATYR0101 is a fusion protein derived from a proprietary extracell...
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Findings highlight ATYR0101's potential as a transformative therapy for disrupting the process of chronic tissue fibrosis. ATYR0101 is currently undergoing IND-enabling studies and expects to be advan...
Why is aTyr Pharma Stock (ATYR) Down 7% Today?
Shares in biopharmaceutical firm aTyr Pharma ($ATYR) dropped 7% today despite hopes that a trial for its lung disease drug efzofitimod was back on track. Its shares had rocketed over…
aTyr Pharma announces alignment with FDA on Phase 3 study of efzofitimod
aTyr Pharma (ATYR) announced that it has reached alignment with the U.S. FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with…
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activit...
aTyr Pharma Proxy statement: Proxy filing
aTyr Pharma filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...
aTyr Pharma Proxy statement: Proxy filing
aTyr Pharma filed a proxy statement on August 31, 2026, providing details for shareholder voting and corporate governance matters.
aTyr Pharma reports Q2 EPS (11c), consensus (13c)
Cash, cash equivalents, restricted cash and available-for-sale investments as of June 30, 2026, were $58.9 million. Based on its current cash and new operating expense forecast and plans, the Company…
aTyr Pharma announces restructuring, will lay off roughly 60% of workforce
aTyr Pharma (ATYR) announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease, including pulmonary sarcoidosis and systemic ...
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately...
aTyr Pharma Quarterly report: Q2 2026
aTyr Pharma has published its Q2 2026 quarterly earnings report on August 7, 2026.
aTyr Pharma Earnings release: Q2 2026
aTyr Pharma released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to F...